07:00 , Jun 30, 2014 |  BC Week In Review  |  Company News

Azanta, Medigene, Will-Pharma sales and marketing update

Medigene said partner Will-Pharma launched Veregen sinecatechins in Belgium to treat genital warts and added that partner Azanta will launch the drug in Denmark and Finland “within the next few weeks.” Will-Pharma has exclusive marketing...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

Azanta, Medigene sales and marketing update

On Dec. 18, 2013, Medigene said partner Azanta launched Veregen sinecatechins in Norway to treat genital warts. Medigene said Azanta will launch Veregen in Sweden early this year. Medigene also said Greece approved Veregen to...
07:00 , Aug 27, 2012 |  BC Week In Review  |  Clinical News

Zybrestat fosbretabulin regulatory update

OxiGene expanded a named-patient program that provides access to Zybrestat fosbretabulin on a compassionate-use basis to treat anaplastic thyroid cancer (ATC) to include South Korea and Israel. The program already provides access to patients in...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Clinical News

Veregen sinecatechins regulatory update

Medigene said Israel, Denmark and Slovakia approved Veregen sinecatechins to treat genital warts. The topical formulation of polyphenols extracted from green tea leaves is already approved in the U.S., Germany, Austria, Switzerland, Spain, France, Sweden...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Company News

Azanta, Medigene sales and marketing update

MediGene granted Azanta exclusive rights to market Veregen sinecatechins in Denmark, Sweden, Norway, Finland and Iceland to treat genital and perianal warts. MediGene will receive an upfront payment and is eligible for double-digit royalties. Azanta...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Clinical News

Zybrestat fosbretabulin regulatory update

OxiGene began a named-patient program to provide access to Zybrestat fosbretabulin to treat anaplastic thyroid cancer (ATC) in Canada and the EU, including Nordic countries and Switzerland. Azanta A/S (Hellerup, Denmark) will manage the program....
08:00 , Dec 6, 2010 |  BC Week In Review  |  Clinical News

Nimoral nimorazole regulatory update

The COMP issued a positive opinion to grant Orphan Drug designation for Azanta's Nimoral nimorazole to treat squamous cell carcinoma of the head and neck (SCCHN) in patients undergoing radiotherapy. The granule formulation of nitroimidazole...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Company News

NeuroSearch management update

NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark   Business: Neurology   Hired: Karin Garre as CMO, effective to Aug. 31, 2011, formerly COO of Azanta A/S  ...